Published in Clin Pharmacokinet on January 01, 2005
Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc (2011) 1.20
Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am J Transplant (2008) 0.95
Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients. Clin Ophthalmol (2010) 0.92
Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. Antimicrob Agents Chemother (2009) 0.84
Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Antimicrob Agents Chemother (2009) 0.81
Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis. J Res Med Sci (2014) 0.79
Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients. HPB (Oxford) (2010) 0.78
Thermus thermophilus nucleoside phosphorylases active in the synthesis of nucleoside analogues. Appl Environ Microbiol (2012) 0.77
Pharmacokinetic studies and LC-MS/MS method development of ganciclovir and dipeptide monoester prodrugs in Sprague Dawley rats. Eur J Drug Metab Pharmacokinet (2014) 0.75
Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. Br J Clin Pharmacol (2014) 0.75
Pharmacokinetics of ganciclovir and valganciclovir in the adult horse. J Vet Pharmacol Ther (2013) 0.75
Construction of Metabolism Prediction Models for CYP450 3A4, 2D6, and 2C9 Based on Microsomal Metabolic Reaction System. Int J Mol Sci (2016) 0.75
Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology (2003) 10.11
Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med (2010) 6.26
Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis (2002) 4.65
International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation (2010) 4.00
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes (2012) 3.11
West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario. CMAJ (2003) 3.03
Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut (2012) 2.91
Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans. Hepatology (2012) 2.81
Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl (2010) 2.57
Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl (2013) 2.48
Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation (2013) 2.43
Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol (2007) 2.35
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant (2004) 2.23
Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis (2003) 2.17
Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation (2004) 2.11
Aerobic capacity during cardiopulmonary exercise testing and survival with and without liver transplantation for patients with chronic liver disease. Liver Transpl (2013) 2.05
Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl (2002) 2.00
Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis (2010) 1.98
RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med (2010) 1.94
Challenges in implementing CD4 testing in resource-limited settings. Cytometry B Clin Cytom (2008) 1.88
Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J Hepatol (2013) 1.83
Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis (2007) 1.78
Mucinous cystic neoplasms of the liver: a clinicopathological study and comparison with intraductal papillary neoplasms of the bile duct. Mod Pathol (2011) 1.74
Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. Clin Infect Dis (2009) 1.64
Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis (2009) 1.62
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis (2009) 1.60
Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl (2004) 1.58
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl (2006) 1.56
Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med (2006) 1.55
Distinct microRNA profiles are associated with the severity of hepatitis C virus recurrence and acute cellular rejection after liver transplantation. Liver Transpl (2013) 1.48
Primary pancreatic lymphoma: diagnostic and therapeutic dilemma. Pancreas (2006) 1.47
Alcohol dehydrogenase-specific T-cell responses are associated with alcohol consumption in patients with alcohol-related cirrhosis. Hepatology (2013) 1.47
Cystatin C, an easy and reliable marker for assessment of renal dysfunction in children with liver disease and after liver transplantation. Liver Transpl (2005) 1.47
Herpes viruses in transplant recipients: HSV, VZV, human herpes viruses, and EBV. Infect Dis Clin North Am (2010) 1.47
Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant (2005) 1.45
Use of the end-to-end anastomotic circular stapler for creation of the duodenoenterostomy for enteric drainage of the pancreas allograft [corrected]. J Am Coll Surg (2004) 1.44
Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review. J Clin Neuromuscul Dis (2009) 1.43
Diaphragmatic dysfunction after pediatric orthotopic liver transplantation. Transplantation (2002) 1.43
Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant (2007) 1.43
Longer-term outcomes after kidney transplantation from seronegative deceased donors at increased risk for blood-borne viral infection. Transplantation (2011) 1.42
Richard Freeman on yoga as a path to physical and spiritual health. Interview by Bonnie Horrigan. Altern Ther Health Med (2004) 1.39
Comparison of a new fibrin sealant with standard topical hemostatic agents. Arch Surg (2004) 1.39
Is surveillance for multidrug-resistant enterobacteriaceae an effective infection control strategy in the absence of an outbreak? J Infect Dis (2002) 1.37
A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation (2010) 1.35
Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation (2004) 1.31
Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant (2004) 1.27
Spontaneous rupture of hepatocellular carcinoma: a Western experience. Am J Surg (2008) 1.25
Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis (2012) 1.25
Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol (2006) 1.24
Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol (2011) 1.20
Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant (2005) 1.19
Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther (2003) 1.18
An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis (2005) 1.14
Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes. PLoS One (2011) 1.14
Implementing recovery: an analysis of the key technologies in Scotland. Int J Ment Health Syst (2011) 1.14
The report of a national conference on the wait list for kidney transplantation. Am J Transplant (2003) 1.14
Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative? Transplantation (2015) 1.13
Management of neuroendocrine liver metastases. Am J Surg (2004) 1.13
Liver transplantation for Budd-Chiari syndrome. Transplantation (2002) 1.12
Presensitization: the problem and its management. Clin J Am Soc Nephrol (2006) 1.12
MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology (2009) 1.11
Metabolic assessment of human liver transplants from biopsy samples at the donor and recipient stages using high-resolution magic angle spinning 1H NMR spectroscopy. Anal Chem (2005) 1.11
Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis (2002) 1.11
Pseudoaneurysm following laparoscopic cholecystectomy. Hepatobiliary Pancreat Dis Int (2007) 1.10
State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis (2012) 1.10
Emergency liver transplantation following severe liver trauma. Liver Transpl (2008) 1.09
A seroprevalence study of west nile virus infection in solid organ transplant recipients. Am J Transplant (2004) 1.09
Cutaneous cryptococcosis in solid organ transplant recipients. Med Mycol (2010) 1.09
In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies (2004) 1.09
Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis (2004) 1.08
Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay. J Clin Microbiol (2011) 1.08
Ruptured hepatocellular carcinoma following chemoembolization: a western experience. Hepatobiliary Pancreat Dis Int (2007) 1.08
Selective embolization for bleeding visceral artery pseudoaneurysms in patients with pancreatitis. Hepatobiliary Pancreat Dis Int (2010) 1.07
Reproducibility of low galactomannan enzyme immunoassay index values tested in multiple laboratories. J Clin Microbiol (2005) 1.07
The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation (2011) 1.07
How we treat sickle hepatopathy and liver transplantation in adults. Blood (2014) 1.07
The development of new density gradient media for purifying human islets and islet-quality assessments. Transplantation (2004) 1.07
Allograft loss in renal transplant recipients with cryptococcus neoformans associated immune reconstitution syndrome. Transplantation (2005) 1.05
A longitudinal molecular surveillance study of human polyomavirus viremia in heart, kidney, liver, and pancreas transplant patients. J Infect Dis (2005) 1.05
Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther (2009) 1.05
Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl (2004) 1.04